2022 PROSTATE CANCER PATIENT CONFERENCE
LIVE VIRTUALLY SEPTEMBER 10-11, 2022 | 8:30 AM PDT
LEARN MORE ABOUT PROSTATE CANCER TREATMENTS, SIDE EFFECTS, & LIFESTYLE
DAY 1 | CLICK THE VIDEO ABOVE TO WATCH
DAY 2 | CLICK THE VIDEO ABOVE TO WATCH
The 2022 Prostate Cancer Patient Conference is a two-day online educational event for prostate cancer patients and caregivers. Join other patients and caregivers who will be attending from across the US and internationally. Renowned physicians from different specialties will be covering topics including advanced cancer, active surveillance, radiation treatment, imaging, erectile dysfunction, and incontinence. The conference is led by Mark Moyad, MD, who moderates the Q+A sessions following each lecture and ensures that our speaker’s answers are relevant to laypeople who are affected by prostate cancer. At the end of the conference, Drs. Mark Scholz and Mark Moyad host an extended Q+A session covering topics and questions that have been submitted by attendees.
*Please note, this broadcast will remain posted here indefinitely and on our YouTube channel for viewing after the broadcast is over.
OUR SPEAKERS
2022 SPEAKERS + TOPICS
Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Health Sciences Centre
Active Surveillance
Evan Yu, MD
Clinical Research Director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance
ADVANCED PROSTATE CANCER TREATMENT & SIDE EFFECTs
Eugene Kwon, MD
Professor of Urology, Professor of Immunology
Mayo Clinic
An UPDATE ON PROSTATE IMAGING
Geoffrey Johnson, MD, PhD
Chair of the Nuclear Medicine Division, Mayo Clinic
PSMA & Prostate CAncer
Jeffrey Brady, MD
Urologist,
AdventHealth Medical Group
INCONTINENCE TREATMENT OPTIONS | surgical & NON SURGICAL
Mark Scholz, MD
Medical Director, Prostate Oncology Specialists &
Executive Director, PCRI
9TH Annual Moyad and Scholz Free for All! Any question on any aspect of prostate cancer!!
Mark Moyad, MD, MPH
Jenkins/Pokempner Director of Preventive and Alternative Medicine Education, University of Michigan, Department of Urology
9TH Annual Moyad and Scholz Free for All! Any question on any aspect of prostate cancer!!
AGENDA
Saturday, September 10, 2022 (all times in PAcific Daylight Time)
8:30am - 9:00am PDT | Opening Remarks with Mark Moyad, MD
9:00am - 11:00am PDT | PSMA Prostate Imaging with Geoffrey Johnson, MD PhD
11:00am - 1:00pm PDT | Incontinence & Erectile Dysfunction with Jeffrey Brady, MD
1:00pm - 1:30pm PDT | Learn More About Erleada with Alec Koo, MD | Sponsored Presentation
1:30pm - 4:00pm PDT | An Update on Active Surveillance with Laurence Klotz, MD
4:00pm PDT | Closing Remarks
SUNDAY, September 11, 2022
8:30am - 10:30am PDT | Advanced Prostate Cancer Treatments with Evan Yu, MD
10:30am - 12:30pm PDT | 177 PSMA Lutetium (Pluvicto) with Eugene Kwon, MD
12:30am - 1:00pm PDT | Learn More About Nubeqa with Kelli Gingerich MSN, CRNP | Sponsored Presentation
1:00pm - 3:30pm PDT | 2022 Update - Bring it on! 9th Annual Moyad and Scholz Free for All! Any Question on Any Aspect of Prostate Cancer! | Mark Moyad, MD & Mark Scholz, MD
3:30pm | Closing Remarks
*Agenda is subject to change
LEARN MORE ABOUT PCRI’S IMPACT
The PCRI provides resources for prostate cancer patients and caregivers looking to gain understanding, insight, and hope. Get honest answers from science based data.
Hello Researcher! We are the Prostate Cancer Research Institute (PCRI), a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for you. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call us at 1 (800) 641-7274 with any question that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
